Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mina Nikanjam

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Cancer|January 2, 2024
Critical insights into the evolving drug-approval process in ChinaMina Nikanjam, Razelle Kurzrock
Med (New York, N.Y.)|January 10, 2026
Trojan horses at leptomeningeal cellular gates: Antibody-drug conjugates deliver cytotoxic payloadsMina Nikanjam, Razelle Kurzrock
Seminars in Cancer Biology|November 1, 2025
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategiesMina Nikanjam, Razelle Kurzrock
Journal of Hematology & Oncology|September 12, 2022
Liquid biopsy: current technology and clinical applicationsMina Nikanjam, Shumei Kato, Razelle Kurzrock
Oncotarget|January 30, 2016
Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancersSariah Liu, Mina Nikanjam, Razelle Kurzrock
Oncoimmunology|September 19, 2017
Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patternsMina Nikanjam, Harsh Patel, Razelle Kurzrock
International Journal of Cancer|July 9, 2016
Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013Mina Nikanjam, Sariah Liu, Razelle Kurzrock
Journal of Immunotherapy and Precision Oncology|December 9, 2022
Of Mice, Not Men: When the Bench-to-Bedside Bridge Is BrokenMina Nikanjam, Shumei Kato, Razelle Kurzrock
Cancer Chemotherapy and Pharmacology|September 5, 2019
Population pharmacokinetics of siltuximab: impact of disease stateMina Nikanjam, Jin Yang, Edmund V Capparelli
Nature Reviews. Drug Discovery|March 6, 2025
Tumour-agnostic kinase inhibitorsJacob J Adashek, Mina Nikanjam, Razelle Kurzrock
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Cancer|January 2, 2024
Critical insights into the evolving drug-approval process in ChinaMina Nikanjam, Razelle Kurzrock
Med (New York, N.Y.)|January 10, 2026
Trojan horses at leptomeningeal cellular gates: Antibody-drug conjugates deliver cytotoxic payloadsMina Nikanjam, Razelle Kurzrock
Seminars in Cancer Biology|November 1, 2025
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategiesMina Nikanjam, Razelle Kurzrock
Journal of Hematology & Oncology|September 12, 2022
Liquid biopsy: current technology and clinical applicationsMina Nikanjam, Shumei Kato, Razelle Kurzrock
Oncotarget|January 30, 2016
Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancersSariah Liu, Mina Nikanjam, Razelle Kurzrock
Oncoimmunology|September 19, 2017
Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patternsMina Nikanjam, Harsh Patel, Razelle Kurzrock
International Journal of Cancer|July 9, 2016
Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013Mina Nikanjam, Sariah Liu, Razelle Kurzrock
Journal of Immunotherapy and Precision Oncology|December 9, 2022
Of Mice, Not Men: When the Bench-to-Bedside Bridge Is BrokenMina Nikanjam, Shumei Kato, Razelle Kurzrock
Cancer Chemotherapy and Pharmacology|September 5, 2019
Population pharmacokinetics of siltuximab: impact of disease stateMina Nikanjam, Jin Yang, Edmund V Capparelli
Nature Reviews. Drug Discovery|March 6, 2025
Tumour-agnostic kinase inhibitorsJacob J Adashek, Mina Nikanjam, Razelle Kurzrock
Pageof 7